Moneycontrol PRO

Buy Healthcare Global Enterprises; target of Rs 370: ICICI Direct

ICICI Direct is bullish on Healthcare Global Enterprises recommended buy rating on the stock with a target price of Rs 370 in its research report dated November 12, 2022.

November 22, 2022 / 07:58 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Healthcare Global Enterprises

HCG operates one of the largest private cancer care networks in India with end-to-end solutions available under a single corporate entity. Owing to exclusive agreement with vendors, HCG procures equipment on a deferred payment basis. Milann offers seven fertility centres in India. HCG network has 22 comprehensive cancer centres (one in Kenya), four multi-specialty hospitals. HCG India, capacity beds: 1944; 1702 operational • Revenue mix FY22: HCG:96%, Milann:4%; occupancy FY22: 58.3%; ARPOBD FY22: 36,697.


Maintain BUY due to 1) improvement in occupancies sustainable, 2) newer assets to turn profitable and complement existing centres and 3) calibrated expansion of moving in metros and non-metros now coming to the fore. We value HCG at Rs 370 (HCG existing centres and new centres at 13x & 11x, respectively, at FY24E EV/EBITDA and Milan centres at 1x FY24E EV/sales).

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Healthcare Global Enterprises - 14 -11-2022 - icici

Broker Research
first published: Nov 22, 2022 07:58 pm